BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 36896801)

  • 1. The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis.
    Leite M; Sampaio F; Saraiva FA; Diaz SO; Barros AS; Fontes-Carvalho R
    ESC Heart Fail; 2023 Jun; 10(3):1822-1834. PubMed ID: 36896801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Systematic Review and Network Meta-Analysis.
    Zafeiropoulos S; Farmakis IT; Milioglou I; Doundoulakis I; Gorodeski EZ; Konstantinides SV; Cooper L; Zanos S; Stavrakis S; Giamouzis G; Butler J; Giannakoulas G
    JACC Heart Fail; 2024 Apr; 12(4):616-627. PubMed ID: 37656079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Heart Failure Pharmacotherapies in Patients with Heart Failure with Mildly Reduced Ejection Fraction.
    Schupp T; Bertsch T; Reinhardt M; Abel N; Schmitt A; Lau F; Abumayyaleh M; Akin M; Weiß C; Weidner K; Behnes M; Akin I
    Eur J Prev Cardiol; 2024 Mar; ():. PubMed ID: 38513366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction.
    Tromp J; Ouwerkerk W; van Veldhuisen DJ; Hillege HL; Richards AM; van der Meer P; Anand IS; Lam CSP; Voors AA
    JACC Heart Fail; 2022 Feb; 10(2):73-84. PubMed ID: 34895860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Network meta-analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction.
    De Marzo V; Savarese G; Tricarico L; Hassan S; Iacoviello M; Porto I; Ameri P
    J Intern Med; 2022 Aug; 292(2):333-349. PubMed ID: 35332595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials.
    Bao J; Kan R; Chen J; Xuan H; Wang C; Li D; Xu T
    Pharmacol Res; 2021 Jul; 169():105573. PubMed ID: 33766629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis.
    Danielson C; Lileikyte G; Ouwerkerk W; S P Lam C; Erlinge D; Teng TK
    ESC Heart Fail; 2022 Aug; 9(4):2753-2761. PubMed ID: 35603531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative cardiovascular outcomes of novel drugs as an addition to conventional triple therapy for heart failure with reduced ejection fraction (HFrEF): a network meta-analysis of randomised controlled trials.
    Suebsaicharoen T; Chunekamrai P; Yingchoncharoen T; Tansawet A; Issarawattana T; Numthavaj P; Thakkinstian A
    Open Heart; 2023 Nov; 10(2):. PubMed ID: 37940331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
    Xiang B; Zhang R; Wu X; Zhou X
    JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction.
    Fu M; Pivodic A; Käck O; Costa-Scharplatz M; Dahlström U; Lund LH
    Clin Res Cardiol; 2023 Jan; 112(1):167-174. PubMed ID: 36443599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis.
    Sreenivasan J; Malik A; Khan MS; Lloji A; Hooda U; Aronow WS; Lanier GM; Pan S; Greene SJ; Murad MH; Michos ED; Cooper HA; Gass A; Gupta R; Desai NR; Mentz RJ; Frishman WH; Panza JA
    Cardiol Rev; 2024 Mar-Apr 01; 32(2):114-123. PubMed ID: 36576372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure.
    Kim HJ; Jo SH; Lee MH; Seo WW; Choi JO; Ryu KH
    Adv Ther; 2020 Sep; 37(9):3839-3849. PubMed ID: 32676928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry.
    Tomasoni D; Pagnesi M; Colombo G; Chiarito M; Stolfo D; Baldetti L; Lombardi CM; Adamo M; Maggi G; Inciardi RM; Loiacono F; Maccallini M; Villaschi A; Gasparini G; Montella M; Contessi S; Cocianni D; Perotto M; Barone G; Merlo M; Cappelletti AM; Rosano G; Sinagra G; Pini D; Savarese G; Metra M
    Eur J Heart Fail; 2024 Feb; 26(2):327-337. PubMed ID: 37933210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Traditional Heart Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure.
    Yan CL; Gallo RA; Vasquez Martinez M; Rivera Rodriguez B; Trujillo L; Thakkar Rivera N; Hoffman JE
    Am J Cardiol; 2023 Oct; 204():360-365. PubMed ID: 37573615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
    Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Efficacy of Medical Treatments for Chronic Heart Failure: A Network Meta-Analysis.
    Xiang B; Yu Z; Zhou X
    Front Cardiovasc Med; 2021; 8():787810. PubMed ID: 35097007
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Chronic Heart Failure in Advanced Chronic Kidney Disease: The HAKA Multicenter Retrospective Real-World Study.
    Quiroga B; Ortiz A; Núñez S; Kislikova M; González Sanchidrián S; Broseta JJ; Albines ZS; Escamilla Cabrera B; Rivero Viera Y; Rodriguez Santarelli D; Salanova Villanueva L; Lopez Rodriguez F; Cancho Castellano B; Ibáñez Cerezon M; Gutierrez Rivas CP; Aresté N; Campos Gutiérrez B; Ródenas Gálvez A; Glucksmann Pizá MC; Balda Manzanos S; Soldevila A; Rodríguez Gayo L; Moral Berrio E; Ortega Diaz M; Beltrán Catalán S; Puente García A; Ángel Rojas M; Sosa Barrios RH; Santana Zapatero H; Rangel Hidalgo G; Martinez Canet AM; Díez J;
    Cardiorenal Med; 2024; 14(1):202-214. PubMed ID: 38513622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.